Immune checkpoint blockade for hematologic malignancies: a review
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Immune checkpoint blockade has revolutionized the treatment of cancer, with impressive responses seen in a broad variety of tumor types. Blockade of immune checkpoints and immune signaling antibodies has shown promise in multiple types of hematologic malignancies (HMs), with dramatic single agent responses for pembrolizumab and nivolumab in Hodgkin lymphoma (HL). In this review, we outline the current state of immune checkpoint blockade drug development in HMs, and discuss mechanisms of activity and resistance, and highlight potential targets in the immune tumor microenvironment (TME). Blockade of T-cell checkpoint molecules PD-1/PD-L1 and CTLA-4 are the most clinically mature of the immune checkpoint strategies. Novel and upcoming strategies for immune checkpoint blockade drug development in HMs using innovative combinations to modulate immunologic targets shows significant promise as a way to expand the number of patients with blood cancers who could benefit from immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 1×
“PD-1 blockade PD-1 pathway blockade with nivolumab (11-15), pembrolizumab (16,17), atezolizumab (18), and durvalumab (MEDI4736) (19,20) has demonstrated activity in multiple solid tumor malignancies.”
BackgroundMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“However, data from melanoma patients treated with PD-1 blockade demonstrating alterations in β2M and loss of MHC class I led to disease progression and resistance to PD-1 blockade immunotherapy (113), suggesting that efficacy of PD-1 blockade in cHL may be independent of antigen presentation by the malignant cell.”
BackgroundCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222 · cited 1×
“com Page 2 of 21 results in CTLA-4 upregulation on the T cell, and through competitive binding to the co-stimulatory molecules CD80/ CD86, negatively modulates activated T cells (3).”
BackgroundMajeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635 · cited 1×
“Although, identification of tumor types with PD-L1 expression in the TME identifies subsets of patients who benefit from checkpoint blockade, PD-1 ligand expression does not guarantee a response nor does its absence exclude the possibility of response to checkpoint blockade (7).”
BackgroundInhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415 · cited 1×
“PD-1 blockade PD-1 pathway blockade with nivolumab (11-15), pembrolizumab (16,17), atezolizumab (18), and durvalumab (MEDI4736) (19,20) has demonstrated activity in multiple solid tumor malignancies.”
BackgroundLesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001 · cited 8×
“The CheckMate 039 study included 23 patients with T-NHL treated with nivolumab monotherapy in which there were 4 PRs, 2/13 in MF and 2/5 in peripheral T cell lymphoma (PTCL) (44).”
BackgroundMethodSelf-citationDubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987 · cited 1×
“Early data in melanoma suggests gut microbiota may play a role in development of colitis, however for the most part predictors of toxicity from immune checkpoint inhibitors are lacking (110).”
BackgroundHodi, F. S., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30366-7 · Cited by 968 · cited 1×
“PD-1 blockade PD-1 pathway blockade with nivolumab (11-15), pembrolizumab (16,17), atezolizumab (18), and durvalumab (MEDI4736) (19,20) has demonstrated activity in multiple solid tumor malignancies.”
Background
Cited by
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Wu, K., Yi, M., Qin, S., Chu, Q., Zheng, X., & Wu, K. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0150-0 · Cited by 96
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40
“As a negative regulator of T cell activation, upregulation of CTLA-4 could also be found in T cells from MM patients and could negatively regulate activated T cells by competitive binding to the costimulatory factor CD80/86 [30].”
BackgroundPeptide‐based targeted therapeutics and apoptosis imaging probes for cancer therapy
Vadevoo, S. M. P., Gurung, S., Khan, F., Haque, M. E., Gunassekaran, G. R., Chi, L., Permpoon, U., & Lee, B. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01125-0 · Cited by 38
Metadata
- Authors
- Pianko, M. J., Liu, Y., Bagchi, S., & Lesokhin, A. M.
- Venue
- Stem Cell Investigation
- Publisher
- AME Publishing Company
- Published
- 2017-04-19
- Volume
- 4
- Pages
- 32-32
- ISSN
- 2306-9759 (ISSN-L)
- 2313-0792
- OpenAlex
- W2608745553
- Cited by
- 62
- References
- 14
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.